A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients with Advanced Solid Tumors or Lymphoma (EZN-2208-01).
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2015
At a glance
- Drugs Firtecan pegol (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 14 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2007 New trial record.